Invuity, Inc. (IVTY) Given Average Rating of “Buy” by Brokerages

Invuity, Inc. (NASDAQ:IVTY) has earned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $11.67.

Several equities research analysts have weighed in on the company. Zacks Investment Research cut Invuity from a “hold” rating to a “sell” rating in a research note on Thursday, September 28th. Piper Jaffray Companies restated a “buy” rating and set a $12.00 target price on shares of Invuity in a research note on Friday, November 10th. Finally, Northland Securities restated a “buy” rating and set a $13.00 target price on shares of Invuity in a research note on Tuesday, September 26th.

Invuity (NASDAQ:IVTY) remained flat at $$6.05 during midday trading on Friday. The company’s stock had a trading volume of 108,300 shares, compared to its average volume of 110,067. The company has a quick ratio of 2.47, a current ratio of 2.90 and a debt-to-equity ratio of 5.39. Invuity has a fifty-two week low of $5.75 and a fifty-two week high of $9.70. The stock has a market capitalization of $103.69, a P/E ratio of -2.45 and a beta of -0.25.

Invuity (NASDAQ:IVTY) last released its earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.04. Invuity had a negative return on equity of 212.38% and a negative net margin of 111.43%. The firm had revenue of $9.60 million during the quarter, compared to analysts’ expectations of $9.87 million. research analysts predict that Invuity will post -2.41 earnings per share for the current year.

Several large investors have recently made changes to their positions in the company. CAPROCK Group Inc. increased its holdings in shares of Invuity by 28.6% during the third quarter. CAPROCK Group Inc. now owns 45,000 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 10,000 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Invuity during the second quarter worth $101,000. Renaissance Technologies LLC acquired a new position in shares of Invuity during the first quarter worth $151,000. Lyon Street Capital LLC increased its holdings in shares of Invuity by 5.2% during the second quarter. Lyon Street Capital LLC now owns 764,530 shares of the medical instruments supplier’s stock worth $5,543,000 after buying an additional 37,498 shares in the last quarter. Finally, OxFORD Asset Management LLP acquired a new position in shares of Invuity during the second quarter worth $374,000. Institutional investors own 69.06% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Invuity, Inc. (IVTY) Given Average Rating of “Buy” by Brokerages” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/05/invuity-inc-ivty-given-average-rating-of-buy-by-brokerages.html.

About Invuity

Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.

Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply